Talimogene laherparepvec (T-VEC) demonstrates efficacy in cutaneous BCC, enhancing resectability and altering immune cell ...

The probability of freedom from recurrence 5 years after surgical excision was higher than with a noninvasive approach in patients with nodular basal cell carcinoma, although the analysis did not show ...

A phase II trial reports success with an innovative immunotherapy for difficult-to-resect basal cell carcinoma, reducing ...